文献速递临床试验与 GCP

脑损伤与氯胺酮研究(BIKe):一项前瞻性随机对照双盲临床试验,研究氯胺酮对重型创伤性脑损伤患者治疗强度水平和颅内压的影响

Brain Injury and Ketamine study (BIKe): a prospective, randomized controlled double blind clinical trial to study the effects of ketamine on therapy intensity level and intracranial pressure in severe traumatic brain injury patients.
PubMed 文献 · Trials · 2025-05-28

BIKe研究是一项前瞻性多中心双盲安慰剂对照随机对照试验,评估氯胺酮作为标准镇静方案辅助用药在重型创伤性脑损伤患者中的安全性及降低颅内压的治疗强度效果。计划纳入100例成人患者,随机接受氯胺酮1 mg/kg/h持续输注或安慰剂,主要安全性终点为每ICU住院期间高颅内压发作中位数增加2次,并假设治疗强度水平评分至少降低3分。

要点

  • 氯胺酮作为重型TBI标准镇静辅助用药的安全性和降低颅内压效果尚无前瞻性RCT证实。
  • 研究药物剂量为1 mg/kg/h持续输注,随机后6小时内开始,末次颅内压控制镇静药停用时停止。
  • 计划纳入100例患者,把握度基于检测每ICU住院期间高颅内压发作中位数增加2次的安全性终点。

核心结论

  • 本研究是首个探讨氯胺酮作为标准镇静方案辅助用药在重型TBI患者中安全性的前瞻性随机对照试验。

研究设计与样本

  • 前瞻性多中心双盲安慰剂对照随机对照试验,计划纳入100例成人重型TBI患者,入住ICU后72小时内需要镇静和颅内压监测者随机接受氯胺酮或安慰剂。
  • 研究药物为1 mg/kg/h持续输注,随机后6小时内开始,末次颅内压控制镇静药停用时停止;数据收集至患者出ICU,所有患者创伤后随访6个月。

主要发现

  • 研究把握度基于安全性终点:检测每ICU住院期间高颅内压发作中位数增加2次具有临床意义的增加。
  • 研究假设治疗强度水平评分至少降低3分具有临床意义。

关键数值与推荐

  • 研究药物剂量为1 mg/kg/h持续输注。
  • 主要安全性终点为每ICU住院期间高颅内压发作中位数增加2次。
  • 假设治疗强度水平评分至少降低3分。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In severe traumatic brain injury (TBI), sedatives are often used to control intracranial pressure (ICP), to reduce brain metabolism, to allow for other treatments such as mechanical ventilation or targeted temperature management, or to control paroxysmal sympathetic hyperactivity. Prolonged sedation is often necessary. The most commonly used sedatives in TBI are propofol and midazolam, often in combination, but both have significant side effects when used at high doses for several days. Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, provides sedation and analgesia with minimal respiratory depression or haemodynamic instability. However, ketamine carries a US Food and Drug Administration (FDA) precaution regarding its use in patients with pre-anaesthetic elevated cerebrospinal fluid pressure, which discourages its use in TBI patients. Several observational studies and two large meta-analyses do not suggest that the use of ketamine as an induction agent or sedative in sedated and mechanically ventilated TBI patients would increase the ICP. Off-label use of ketamine for this indication is increasing worldwide. To date, no prospective randomized clinical trial (RCT) has demonstrated the safety of ketamine in TBI patients. METHODS: The Brain Injury and Ketamine (BIKe) study is a prospective multicentre double-blind placebo-controlled RCT, to evaluate the safety, and effect on therapeutic intensity to reduce ICP, of ketamine as an adjunct to a standard sedation regimen in patients with severe TBI. Adult TBI patients, admitted to the intensive care unit (ICU), requiring sedation and ICP monitoring within 72 h of admission, will be randomized to ketamine or placebo. The study drug will be started within 6 h of randomization. The dose of the investigational medicinal product (IMP) is 1 mg/kg/h, by continuous infusion. The IMP will be stopped when the last ICP control sedative is discontinued. Data collection will stop when the patient is discharged from the ICU. All patients will be followed for 6 months post-trauma. The study is powered for the safety endpoint of detecting a clinically relevant increase of two episodes in the median number of episodes of high intracranial pressure episodes per ICU stay. A total of 100 patients are required to meet these objectives. We hypothesize a clinically relevant reduction in the therapeutic intensity level (TIL) score of at least 3 points. DISCUSSION: This study is the first prospective RCT to investigate the safety of ketamine as an adjunct to a standard sedation regimen in TBI patients. TRIAL REGISTRATION: ClinicalTrials.gov NCT05097261. Registered on October 28, 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. De Sloovere V, Mebis L, Wouters P, et al. Brain Injury and Ketamine study (BIKe): a prospective, randomized controlled double blind clinical trial to study the effects of ketamine on therapy intensity level and intracranial pressure in severe traumatic brain injury patients. Trials. 2025. PMID: 40437634. doi:10.1186/s13063-025-08835-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。